Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MVA-MUC1-IL2 vaccine |
Synonyms | |
Therapy Description |
MVA-MUC1-IL2 (TG4010) is a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2), for immunotherapy in cancer patients whose tumors express the MUC1 antigen (PMID: 28923084). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MVA-MUC1-IL2 vaccine | TG4010 | MVA-MUC1-IL2 (TG4010) is a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2), for immunotherapy in cancer patients whose tumors express the MUC1 antigen (PMID: 28923084). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01383148 | Phase Ib/II | MVA-MUC1-IL2 vaccine | Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer | Terminated | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | BEL | 0 |